As we know, the most prestigious example of DRG is MGMT in glioma, which was demonstrated as a prognostic indicator to predict the therapeutic advantage of chemotherapy regimen, for example, nitrosoureas (Esteller et al., 2000) and temozolomide (Hegi et al., 2004). This evidence concerns the gene MGMT and central nervous system cancer.